Gillian Hirst, PhD
Associate Professor
Surgery
School of Medicine

Awards

Show all (1) Hide

• CRC Post-Doctoral Fellowship, Beatson Institute, University of Glasgow, 1993-1999

Education & Training

Show all (4) Hide

• Teach for UCSF Certificate in Education Leadership University of Californa 2021
• Diversity, Equity, and Inclusion Champion Training University of California 2019
• PhD Molecular Oncology University of Edinburgh
• BSc Physiological Sciences University of Newcastle Upon Tyne

Websites

Show all (1) Hide

• UCSF T32 Surgical Oncology (t32surgicaloncology.ucsf.edu)

Grants and Projects

Show all (7) Hide

• Surgical Oncology Training Grant, NIH, 2020-2025
• I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes, NIH, 2017-2022
• Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers, NIH, 2015-2021
• Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes, NIH, 2014-2020
• Science Leadership and Integration, NIH, 2009-2015
• A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response, NIH, 1999-2015
• Program Project Grant, NIH, 2003-2010

Publications (52)

Top publication keywords:
Antineoplastic Combined Chemotherapy ProtocolsTriple Negative Breast NeoplasmsNeoadjuvant TherapyRadiation Injuries, ExperimentalBreast NeoplasmsCirculating Tumor DNACarcinoma, Intraductal, NoninfiltratingTrinucleotide Repeat ExpansionNeoplasms, Radiation-InducedCarcinogenesisBiological Specimen BanksGenetic TechniquesPaclitaxelReceptor, ErbB-2Trastuzumab

• Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer.
  NPJ breast cancer 2024 Kulkarni AA, Jain A, Jewett PI, Desai N, Van 't Veer L, Hirst G, Yee D, Blaes AH, ISPY2 consortium
• Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
  bioRxiv : the preprint server for biology 2024 Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Yu S, Hirst G, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H
• Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer …
• Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy…
• Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
  Cell reports. Medicine 2023 Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, …

Show all (47 more) Hide

• Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
  JAMA network open 2023 Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, …
• B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
  Breast cancer research : BCR 2023 Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, …
• Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
  Frontiers in oncology 2023 Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M
• Development and testing of a polygenic risk score for breast cancer aggressiveness.
  NPJ precision oncology 2023 Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer…
• Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
  Cancer cell 2023 Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, …
• Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
  Breast cancer research and treatment 2023 Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ
• Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
  Cancer research communications 2022 Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ
• Cancer Prevention Research
  Abstract PR008: Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers 2022 Thomas O'Keefe; Christina Yau; Emma Iaconetti; Eliza Jeong; Case Brabham; Paul Kim; Joseph McGuire; Ann Griffin; Laura Esserman; Olivier Harismendy; Gillian Hirst
• Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
  NPJ breast cancer 2022 Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS,…
• Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
  Cancer cell 2022 Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, …
• The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
  NPJ breast cancer 2022 Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O
• Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
  The Lancet. Oncology 2021 Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 …
• Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
  Nature communications 2021 Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis …
• Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
  NPJ breast cancer 2021 Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, …
• Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM, I-SPY2 Trial Team
• Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
  Cancer cell 2021 Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, …
• PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
  JAMIA open 2021 O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A
• Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
  NPJ breast cancer 2021 Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L
• Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R,…
• Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H…
• Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
  BMC medical genomics 2020 Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O
• Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME
• Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
  NPJ breast cancer 2020 Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer…
• Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
  JAMA oncology 2020 I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-…
• Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
  Journal of breast imaging 2020 Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators
• Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
  JAMA oncology 2020 Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, …
• The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
  Cell 2020 Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, …
• Mutational signatures in tumours induced by high and low energy radiation in Trp53 deficient mice.
  Nature communications 2020 Rose Li Y, Halliwill KD, Adams CJ, Iyer V, Riva L, Mamunur R, Jen KY, Del Rosario R, Fredlund E, Hirst G, Alexandrov LB, Adams D, Balmain A
• MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, …
• Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
  NPJ breast cancer 2018 Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J,…
• Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
  JCO precision oncology 2018 Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, …
• DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
  NPJ breast cancer 2017 Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, …
• Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer.
  Cell reports 2016 Quigley DA, Kandyba E, Huang P, Halliwill KD, Sjölund J, Pelorosso F, Wong CE, Hirst GL, Wu D, Delrosario R, Kumar A, Balmain A
• Adaptive Randomization of Neratinib in Early Breast Cancer.
  The New England journal of medicine 2016 Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, …
• Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
  The New England journal of medicine 2016 Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS,…
• Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers.
  Nature medicine 2015 McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hirst G, Vuong P, Jen KY, Hewinson J, Adams DJ, Balmain A
• Forty years of cancer modelling in the mouse.
  European journal of cancer (Oxford, England : 1990) 2004 Hirst GL, Balmain A
• Automated fluorescent detection of microsatellite instability.
  Molecular biotechnology 2001 Hirst GL, Illand M
• Detection of the Replication Error Phenotype in Ovarian Cancer-PCR Analysis of Microsatellite Instability.
  Methods in molecular medicine 2001 Hirst GL, Brown R
• Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes.
  Current biology : CB 1999 Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, Borts RH, Brown R
• PCR analysis of microsatellite instability.
  Methods in molecular medicine 1999 Hirst GL
• Estrogen regulation of transforming growth factor-alpha in ovarian cancer.
  The Journal of steroid biochemistry and molecular biology 1998 Simpson BJ, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JM, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF, Miller WR
• hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
  Oncogene 1997 Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA
• Expression of the heat shock protein HSP27 in human ovarian cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 1995 Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, Miller WR
• Growth-control of human ovarian-carcinoma cells by insulin-like growth-factors.
  Oncology reports 1995 Bartlett JM, Rabiasz GJ, Scott WN, Langdon SP, Hirst GL, Lee A, Smyth JF, Miller WR
• The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines.
  The Journal of steroid biochemistry and molecular biology 1994 Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF, Miller WR
• Identification of M cells and their distribution in rabbit intestinal Peyer's patches and appendix.
  Cell and tissue research 1993 Jepson MA, Simmons NL, Hirst GL, Hirst BH